Mico BioMed Co. Ltd. (214610) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has a cash flow conversion efficiency ratio of -0.315x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.13 Billion ≈ $-5.51 Million USD) by net assets (₩25.81 Billion ≈ $17.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mico BioMed Co. Ltd. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Mico BioMed Co. Ltd. for a breakdown of total debt and financial obligations.
Mico BioMed Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samyoung S&C Co. Ltd.
KQ:361670
|
-0.023x |
|
Zenta Group Company Limited Ordinary Shares
NASDAQ:ZGM
|
N/A |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
-12.940x |
|
Edinburgh Investment Trust
LSE:EDIN
|
0.020x |
|
Armlogi Holding Corp. Common Stock
NASDAQ:BTOC
|
-0.086x |
|
Greencore Group
LSE:GNC
|
0.221x |
|
SemiLEDS Corporation
F:6LD1
|
0.174x |
|
Mason Capital Corporation
KQ:021880
|
0.043x |
Annual Cash Flow Conversion Efficiency for Mico BioMed Co. Ltd. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mico BioMed Co. Ltd. from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Mico BioMed Co. Ltd. (214610) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩25.89 Billion ≈ $17.54 Million |
₩-10.70 Billion ≈ $-7.25 Million |
-0.413x | -32.16% |
| 2023-12-31 | ₩36.33 Billion ≈ $24.62 Million |
₩-11.36 Billion ≈ $-7.70 Million |
-0.313x | +60.50% |
| 2022-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-14.01 Billion ≈ $-9.49 Million |
-0.792x | -381.03% |
| 2021-12-31 | ₩52.26 Billion ≈ $35.42 Million |
₩-8.60 Billion ≈ $-5.83 Million |
-0.165x | +50.70% |
| 2020-12-31 | ₩55.96 Billion ≈ $37.92 Million |
₩-18.68 Billion ≈ $-12.66 Million |
-0.334x | +96.73% |
| 2019-12-31 | ₩1.02 Billion ≈ $691.72K |
₩-10.43 Billion ≈ $-7.07 Million |
-10.223x | -759.39% |
| 2018-12-31 | ₩5.71 Billion ≈ $3.87 Million |
₩-6.79 Billion ≈ $-4.60 Million |
-1.190x | -40.61% |
| 2017-12-31 | ₩3.42 Billion ≈ $2.32 Million |
₩-2.89 Billion ≈ $-1.96 Million |
-0.846x | +18.99% |
| 2016-12-31 | ₩3.83 Billion ≈ $2.59 Million |
₩-3.99 Billion ≈ $-2.71 Million |
-1.044x | -- |
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more